Cosette Pharmaceuticals Broadens Branded Portfolio with Acquisition of SYMPAZAN® and Additional Assets from Assertio
Cosette Pharmaceuticals has announced the successful closing of a strategic acquisition that significantly expands its branded product portfolio and reinforces its position in key therapeutic areas. The company has acquired the U.S. sales and distribution rights for a portfolio of seven branded medicines from Assertio Holdings Inc., marking an important milestone in Cosette’s long-term growth strategy.
This transaction reflects Cosette’s disciplined and targeted approach to portfolio expansion, combining the addition of established, revenue-generating products with the integration of a high-growth, patent-protected asset in a specialized therapeutic area. At the center of the acquisition is SYMPAZAN, an FDA-approved treatment for seizures associated with Lennox-Gastaut Syndrome (LGS), a rare and severe form of epilepsy. The inclusion of SYMPAZAN not only strengthens Cosette’s neurology portfolio but also establishes a meaningful presence in the rare disease segment, an area of increasing strategic importance across the pharmaceutical industry.
SYMPAZAN is a unique formulation of clobazam delivered as an oral film, designed to dissolve on the tongue without the need for water. This delivery method provides a practical and patient-friendly alternative to traditional tablet or liquid formulations, particularly for individuals who have difficulty swallowing. As the first and only FDA-approved oral film formulation of clobazam, SYMPAZAN addresses a significant unmet need in the treatment of LGS, a condition characterized by frequent and severe seizures that often begin in early childhood.
The product’s strong clinical profile and differentiated formulation have contributed to its growth trajectory, making it an attractive asset within the acquired portfolio. Importantly, SYMPAZAN benefits from patent protection extending through 2040, providing Cosette with long-term exclusivity and the potential for sustained revenue generation. This aligns with the company’s strategy of investing in durable, high-value assets that can support consistent growth over time.
Apurva Saraf, President and Chief Executive Officer of Cosette Pharmaceuticals, emphasized the strategic rationale behind the acquisition. He noted that the transaction delivers immediate scale through the addition of marketed branded products while also introducing a high-growth asset in an orphan indication. Saraf highlighted that the deal underscores Cosette’s ability to execute complex strategic transactions and reinforces its commitment to expanding its footprint in both established and emerging therapeutic areas.
Beyond SYMPAZAN, the acquisition includes a diversified portfolio of branded non-steroidal anti-inflammatory drugs (NSAIDs) and other therapies that address a range of conditions, including inflammation, pain management, and migraine. These products are widely recognized within their respective markets and contribute to the overall value of the transaction by providing established revenue streams and broadening Cosette’s commercial reach.
Among the acquired products are INDOCIN, available as both an oral suspension and suppository, which is used to treat inflammation and pain associated with various conditions. INDOCIN has a long history of clinical use and remains an important option for patients requiring non-steroidal anti-inflammatory therapy. The portfolio also includes SPRIX, a non-invasive treatment option for short-term management of moderate to severe pain, offering an alternative to injectable formulations.
Additional products in the portfolio include ZIPSOR and CAMBIA, both of which are used in pain management and migraine treatment. These therapies are well-established in clinical practice and provide Cosette with expanded capabilities in addressing common yet impactful conditions that affect a broad patient population.
The acquisition also includes OTREXUP, a subcutaneous formulation of methotrexate. Although Otrexup was discontinued by Assertio in August 2025, its inclusion in the transaction reflects the comprehensive nature of the asset transfer and may offer potential strategic optionality for Cosette in the future.
A key aspect of the transaction is the structured transition period during which responsibilities for manufacturing, supply chain management, commercialization, and regulatory compliance will be transferred from Assertio to Cosette. This includes critical functions such as quality assurance, pharmacovigilance, and regulatory affairs, all of which are essential for maintaining product integrity and ensuring patient safety. The transition is designed to be seamless, minimizing disruption for healthcare providers and patients while enabling Cosette to fully integrate the acquired assets into its operations.
From a strategic standpoint, the acquisition aligns with Cosette’s broader vision of building a robust and diversified branded portfolio. By focusing on products that are already on the market and generating revenue, the company can achieve immediate scale while reducing the risks associated with early-stage development. At the same time, the inclusion of a high-growth, patent-protected asset like SYMPAZAN provides a platform for long-term value creation.
The move into the neurology and rare disease space is particularly noteworthy, as these areas are characterized by high unmet medical need and strong demand for innovative therapies. By establishing a foothold in this segment, Cosette positions itself to participate in a growing market while also contributing to improved outcomes for patients with complex and underserved conditions.
The transaction also highlights the evolving dynamics of the pharmaceutical industry, where companies are increasingly pursuing targeted acquisitions to strengthen their portfolios and drive growth. Rather than relying solely on internal research and development, many organizations are leveraging external opportunities to acquire complementary assets and expand their capabilities. Cosette’s acquisition of Assertio’s portfolio exemplifies this approach, combining strategic asset selection with operational execution.
In addition to expanding its product offerings, the acquisition enhances Cosette’s commercial infrastructure and market presence. The integration of these products will require coordination across multiple functions, including sales, marketing, supply chain, and regulatory affairs. Successfully managing this process will be critical to realizing the full value of the transaction and ensuring continued access to these therapies for patients.
Looking ahead, Cosette is expected to focus on optimizing the performance of the acquired products, leveraging its expertise in commercialization and lifecycle management to drive growth. This may include initiatives to expand market access, enhance patient and provider education, and explore opportunities for further differentiation within each therapeutic category.
The company’s ability to execute on these priorities will be a key determinant of the transaction’s long-term success. However, with a clear strategic vision and a proven track record of growth, Cosette appears well-positioned to capitalize on the opportunities presented by this acquisition.
In conclusion, the acquisition of Assertio’s branded portfolio represents a significant step forward for Cosette Pharmaceuticals, strengthening its position in the specialty pharmaceutical market and advancing its long-term growth strategy. By combining immediate scale with the addition of a high-value, patent-protected asset, the transaction delivers both near-term and future benefits. As Cosette integrates these products and continues to expand its capabilities, the company is poised to play an increasingly important role in delivering innovative and accessible therapies to patients across a range of therapeutic areas.
About Cosette Pharmaceuticals
Cosette Pharmaceuticals, Inc. is a U.S.-based, leading specialty pharmaceutical company providing some of the most trusted and well-known brands in medicine — acquiring, developing, and delivering products that make a difference in patients’ lives. Cosette’s strong growth has been driven by its proven ability to maximize the value of its portfolio through best‑in‑class marketing, promotion, and strategic distribution capabilities, enabling the company to scale efficiently while continuing to invest in high-quality, patient-centered therapies.
Cosette has corporate headquarters in Bridgewater, New Jersey and is supported by 350+ dedicated team members across all functional areas. Cosette is backed by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by Hamilton Lane, a private markets investment management firm (Nasdaq: HLNE).
Source Link:https://www.businesswire.com/
